Ropeginterferon alfa-2b Clinical Trials

3 actively recruiting trials across 1 location

▲ +1 trial since June 2026

Also known as: Besremi, P1101

Pipeline

Phase 1: 1Phase 3: 1

Top Sponsors

PharmaEssentia1
H. Lee Moffitt Cancer Center and Research Institute1
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS1

Indications

Cancer3
Cutaneous T Cell Lymphoma1
Primary Myelofibrosis1
Myeloproliferative Neoplasm1
Polycythemia Vera1

Other2 trials

Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

Phase 3

Tampa, Florida1 trial

Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)

Moffitt Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.